Citadel Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Citadel Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-11,940	Closed	-$1.26M	–	9197
2014 Q4	$1.11M	Buy	11,940 +292	+3%	+$23K	﹤0.01%	3650
2014 Q3	$801K	Sell	11,648 -4,428	-28%	-$317K	﹤0.01%	3997
2014 Q2	$1.69M	Sell	16,076 -15,051	-48%	-$1.28M	﹤0.01%	2911
2014 Q1	$2.58M	Buy	31,127 +26,077	+516%	+$2.41M	﹤0.01%	2390
2013 Q4	$327K	Buy	+5,050	New	+$300K	﹤0.01%	4513

Citadel Advisors's GEVA Position: Q1 2015 in Review

Citadel Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 11,940 shares — an estimated $1.26M sold.

Citadel Advisors first reported a position in GEVA in Q4 2013 and held it in 5 quarters. The position peaked at $2.58M in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Citadel Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Citadel Advisors sold 11,940 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $1.26M.
Citadel Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 5 quarters.
Citadel Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.58M in Q1 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Citadel Advisors's 13F filing for Q1 2015, filed 15 May 2015.